NCT01503970

Brief Summary

The purpose of this study is to assess safety and efficacy of autologous chondrocyte implantation delivered arthroscopically into chondral lesions of the knee using clinical, biochemical, and MRI outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Dec 2008

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2008

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

December 1, 2011

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 4, 2012

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

April 12, 2017

Status Verified

April 1, 2017

Enrollment Period

3 years

First QC Date

December 1, 2011

Last Update Submit

April 11, 2017

Conditions

Keywords

chondral lesionsknee

Outcome Measures

Primary Outcomes (1)

  • Change from baseline to different periods in T2 Mapping for cartilage lesions after treatment.

    Special magnetic resonance imaging technique for measurement of collagen and water content, it is expressed in milliseconds.

    3, 6, 9, 12, 18, 24 36 months

Secondary Outcomes (1)

  • Change of baseline to different periods in Clinical evaluation

    0, 10, 30 days, 3, 6, 9, 12, 24, 36 months

Study Arms (1)

Chondrocyte implantation

EXPERIMENTAL
Device: Arthroscopic matrix encapsulated chondrocyte implantation

Interventions

Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.

Chondrocyte implantation

Eligibility Criteria

Age18 Years - 50 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients with symptomatic chondral lesions of the knee

You may not qualify if:

  • Inflammatory arthritis
  • Septic arthritis
  • Total meniscectomy
  • Previous microfracture at chondral lesions
  • Paget
  • Ochronosis
  • Acromegalia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Rehabilitation Institute

Mexico City, 14389, Mexico

Location

Related Publications (3)

  • Masri M, Lombardero G, Velasquillo C, Martinez V, Neri R, Villegas H, Ibarra C. Matrix-encapsulation cell-seeding technique to prevent cell detachment during arthroscopic implantation of matrix-induced autologous chondrocytes. Arthroscopy. 2007 Aug;23(8):877-83. doi: 10.1016/j.arthro.2007.05.010.

    PMID: 17681210BACKGROUND
  • Ibarra-Ponce de Leon JC, Velasquillo-Martinez MC, Izaguirre A, Villalobos-Cordova E, Masri M, Ibarra-Ibarra LG. [Cartilage repair: cell-based techniques]. Acta Ortop Mex. 2009 Jan-Feb;23(1):38-44. Spanish.

    PMID: 19462773BACKGROUND
  • Ibarra C, Izaguirre A, Villalobos E, Masri M, Lombardero G, Martinez V, Velasquillo C, Meza AO, Guevara V, Ibarra LG. Follow-up of a new arthroscopic technique for implantation of matrix-encapsulated autologous chondrocytes in the knee. Arthroscopy. 2014 Jun;30(6):715-23. doi: 10.1016/j.arthro.2014.02.032. Epub 2014 Apr 18.

    PMID: 24746406BACKGROUND

MeSH Terms

Conditions

Lacerations

Condition Hierarchy (Ancestors)

Wounds and Injuries

Study Officials

  • Clemente Ibarra, M.D.

    INR

    PRINCIPAL INVESTIGATOR
  • Luis Guillermo Ibarra, M.D.

    INR

    STUDY CHAIR
  • Aldo F Izaguirre, M.D.

    INR

    STUDY DIRECTOR
  • Enrique Villalobos, M.D.

    INR

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Study Director

Study Record Dates

First Submitted

December 1, 2011

First Posted

January 4, 2012

Study Start

December 1, 2008

Primary Completion

December 1, 2011

Study Completion

December 1, 2012

Last Updated

April 12, 2017

Record last verified: 2017-04

Locations